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Summary 
Pituitary tumor animal models provide researchers a microenvironment that simulates the 
clinical situation; however, in comparison with astrocytoma and meningioma tumor 
research where intracranial xenograft transplantations are increasingly being used to test 
various therapeutic modalities, in vivo therapeutic research on pituitary animal models 
focuses on direct drug therapy to the tumor because of the lack of established intracranial 
pituitary tumor models. The rat subcutaneous prolactin-secreting pituitary model allows 
investigators to noninvasively measure tumor size and the effect of direct tumor-guided 
therapy in a serial manner and is considered biologically relevant because it has proven to 
be histologically, immunocytochemically, and ultrastructurally consistent with human 
pituitary tumors.  
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1. Introduction 
Pituitary tumors are a broad group that accounts for approximately 15% of all 
symptomatic adult primary intracranial tumors. They are remarkably prevalent, 
present in approximately 20% of the population (1). Most of these tumors are small 
and incidental, but roughly 1 patient in 600–700 requires treatment (2). 
 
Pituitary tumors can be classified by multiple different schemes, including by 
endocrine function, by histological staining methods, and by electron microscopic 
appearance (3). The mean age of affected patients is between 30 and 50 years. 
There is a slight female predominance with prolactin- and adrenocorticotropic 
hormone–secreting tumors and a male predominance in growth hormone–
secreting tumors. Nonfunctioning pituitary adenomas account for 25% of these 
tumors and less than 1% are malignant.  
 
Animal tumor model systems are vital to the process of cancer therapy 
development (4). Pituitary tumor animal models provide researchers a 
microenvironment that simulates the clinical situation. Since 1953 when Furth et 
al. (5) described transplantable pituitary tumors in the rat, numerous constructs 
and induction methods enlisting mouse, rat, and canine models have been 
described (6-9). In comparison with astrocytoma and meningioma tumor research 
where intracranial xenograft transplantations are increasingly being used to test 
various therapeutic modalities, in vivo therapeutic research on pituitary animal 
models focuses on direct drug therapy to the tumor because of the lack of 
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1.1. History of Pituitary Tumor Models 
Early pituitary tumors in animal models were induced by exposing rats to elevated 
levels of estrogen (10). Other methods of inducing tumors included antithyroid 
procedures, carcinogen exposure, and increasing levels of ionized radiation (11). 
Further research with the estrogen-induced tumors showed that these tumors were 
completely hormone dependent and not autonomous neoplasms, making them 
only viable in estrogen-treated hosts (8, 12, 13). Additionally, investigators found 
that these inducible tumors that were transplanted into other animals differed from 
most human pituitary tumors by their malignancy and their undifferentiated 
aspects, reducing their value as a human pituitary neoplasm model (14, 15). 
 
In 1982, Trouillas et al. described spontaneous tumors that arose in the pituitary 
of approximately 70% of all female Wister/Furth rat strains (16, 17). Histological, 
immunocytochemical, and ultrastructural similarities between these spontaneous 
tumors and those found in the human pituitary made this entity a very promising 
animal tumor model for study (16). Initial difficulties using this model included 
the length of time required to mature enough animals with acceptable tumors, the 
small size of the tumors, and the unusual location, making it a difficult and costly 
model for pituitary study. By grafting these spontaneous tumors directly under the 
kidney capsule and subcutaneous region of consanguineous animals within the 
same strain, however, investigators developed an animal model of the pituitary 
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reproducible, and analogous to the human pituitary tumor. This initial cell strain 
was named the spontaneous mammotrophic tumor in Wistar (SMtTW) rats line 
(8). Since that time, other pituitary tumor cell lines that have been shown to have 
similar morphological and functional properties as the SMtTW line include the 
ArT and GH strains. 
 
The rat subcutaneous prolactin-secreting pituitary model allows investigators to 
noninvasively measure tumor size and the effect of direct tumor-guided therapy in 
a serial manner. The results from these studies are considered biologically 
relevant as these animal models have been proved to be histologically, 
immunocytochemically, and ultrastructurally consistent with human pituitary 
tumors (18, 19). The majority of our work has been done with the GH pituitary 
tumor cell line, namely the GH4C1 strain. 
 
2. Materials 
The products and suppliers used are listed below. Comparable products should also be 
effective. 
2.1. Pituitary tumor cell culture 
1. Rat pituitary cell line, such as GH4C1, grown at 37°C in 5% CO2  
2. Growth medium: Ham’s F-10 Nutrient, supplemented with 15% horse and 
2.5% bovine serum in the absence of antibiotics 
3. 10-cm cell culture dishes 
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2.2 Tumor cell implantation and tumor size measurement 
1. GH4C1 cell line at ~80% confluence in 10-cm dishes (maximum of 9 weekly 
passages) 
2. Ice 
3. 0.025% Trypsin 
4. Hemocytometer  
5. Growth medium: Ham’s F-10 Nutrient, supplemented with 15% horse 
and2.5% bovine serum in the absence of antibiotics 
6. 8-week-old female Wistar-Furth rats 
7. Intraperitoneal injections of 100 mg/kg ketamine and 10 mg/kg xylazine 
hydrochloride (Sigma) in phosphate-buffered saline 





3.1. Pituitary tumor cell culture 
1. Grow the GH4C1 tumor cell lines in Ham’s F-10 Nutrient supplemented with 
15% horse and 2.5% bovine serum in the absence of antibiotics to 80% 
confluence in cell culture dishes at 37°C and 5% CO2 (see Note 1). 
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1. Grow cells to approximately 80% confluence in T-175 flasks. 
2. All steps are carried out on ice. 
3. Treat cells with 0.025% trypsin to detach cells from flasks. 
4. Determine cell counts using a bright-light hemocytometer; centrifuge the cells 
at 1000 rpm for 5 minutes at 4°C and resuspend the pellet in medium to obtain 
final cell concentrations of 10
7
 cells per rat in 100 l of growth medium (see 
Note 2). 
5. Anesthetize 8-week-old Wistar-Furth rats with intraperitoneal injections of 
100 mg/kg ketamine and 10 mg/kg xylazine hydrochloride in phosphate-
buffered saline (see Note 3). 
6. Inoculate approximately 1×107 GH4C1 cells subcutaneously between the 
scapulae of each rat. 
7. After implantation, allow tumors to grow in vivo for 28-day period. 
8. After 28-day growth period, determine tumor sizes using surface diameter 
measurements with calipers in three orthogonal directions. 
9. Subsequently, animals can be equally divided so that each group has tumors 
of comparable sizes (see Note 4). 
10. Give animals open access to food, water, and evaluate tumor size three times 
weekly. 
11. Sacrifice animals that appear ill or with neurological deficits in accordance 
with the animal protocol at your institution (see Note 5). 
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4. Notes 
1. Stock cultures are grown on cell culture plates before being transplanted to T-
175 flasks for further passaging. GH4C1 tumor cell line quality begins to 
diminish in regards to replication ability after 10 passages. Therefore, we 
recommend only using cell lines that have undergone a maximum of 9 
passages. 
2. For subcutaneous tumor inoculations in the rat model, we found 107 cells per 
animal to be ideal because of easier visibility of tumor and longer time before 
tumor-related side effects. 
3. Wistar-Furth rats should be allowed to acclimatize for one week prior to 
tumor cell injection. Follow your Institutional Animal Care and Use 
Committee protocols regarding all animal storage and handling.  
4. To minimizing fighting between rats and risk of bodily damage to animals or 
tumor specimens, we use only female rats in our protocol and follow 
institutional guidelines regarding the maximum number of animals per cage. 
5. While it did not occur in our series, all animals, per institutional care 
protocols, that appear ill or show neurologic deficits, should be euthanized.  
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